This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) and oral semaglutide (Rybelsus®). Injections are usually more ...
Pfizer (PFE) stock is in focus as the firm gets FDA priority review for its marketing application seeking a label expansion ...
Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's ...
Asianet Newsable on MSN
Why is ALVO stock rising pre-market today?
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.
REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in ...
Several commonly prescribed RA drugs can be self-injected at home, often using either a prefilled syringe or an auto-injector ...
This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilitiesThe ...
PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...
The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
The FDA is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results